(Q85232153)
Statements
Design and rationale for RE-VERSE AD: A phase 3 study of idarucizumab, a specific reversal agent for dabigatran (English)
Jeffrey I Weitz
Jerrold H Levy
Menno V Huisman
Charles V Pollack
Paul A Reilly
Richard Bernstein
Robert Dubiel
John Eikelboom
Stephan Glund
Elaine Hylek
Chak-Wah Kam
Pieter W Kamphuisen
Joerg Kreuzer
Frank Sellke
Joachim Stangier
Thorsten Steiner